David Solomon

Dr David H Solomon joined as Chief Executive Officer of Thalia Therapeutics in February 2026. David brings over 30 years of international leadership experience in biotechnology, pharmaceuticals, and healthcare innovation. He has held multiple Chief Executive roles at publicly-listed and private biotech companies in both the US and Europe, demonstrating expertise in R&D delivery, strategic business development, financing, corporate governance and delivering significant shareholder value.

David was Chief Executive Officer of Silence Therapeutics plc [NASDAQ: SLN], the Nasdaq-listed RNA therapeutics company. During his tenure the market capitalisation rose from £40 million to over £700 million. Earlier, he served as the Chief Executive Officer of Nasdaq-listed Zealand Pharma A/S [NASDAQ: ZEAL], leading the company through its IPO and the global approval of its lead product, Liixisenatide, a GLP-1 receptor agonist for type II diabetes, marketed by Sanofi as Adlixin® and Soliqua®. David was also Chief Executive Officer of Pharnext S.A., a clinical-stage biopharmaceutical firm focused on novel rare disease therapeutics. He has also served on multiple biotech boards, including as Chairman and Director for companies such as Advicenne and Rexgenero, and has held board positions with TxCell, Onxeo, and Promosome. David was earlier a founder of Carrot Capital Healthcare Ventures in New York City.

David studied at Weill Cornell Medicine of Cornell University and the Sloan Kettering Graduate School of Medical Sciences, where he received his PhD. He also served on the faculty of Columbia University’s College of Physicians & Surgeons, in the departments of Pharmacology, Neurology and Biological Sciences.